ライフサイエンスコーパス: infliximab

1 pathic arthritis, and most were treated with infliximab.

2 -tumor necrosis factor (TNF) agents, such as infliximab.

3 on between fecal and serum concentrations of infliximab.

4 ed with the separation of charge variants of Infliximab.

5 ons continued while receiving treatment with infliximab.

6 raining lymph nodes following treatment with infliximab.

7 unomodulatory monoclonal antibodies, such as infliximab.

8 llocated to have resection and 70 to receive infliximab.

9 receive laparoscopic ileocaecal resection or infliximab.

10 lapse within 1 year after discontinuation of infliximab.

11 ioprine, mycophenolic acid, methotrexate, or infliximab.

12 nts and the role of cyclosporine compared to infliximab.

13 ated process that is potentially impacted by infliximab.

14 marketed drugs daclizumab, bevacizumab, and infliximab.

15 ctors were receipt of corticosteroids and/or infliximab.

16 were identified following the initiation of infliximab.

17 plete mucosal healing) or did not respond to infliximab.

18 A single intravitreal injection of infliximab (1 mg/0.05 mL) was given to 15 patients with

19 eerts scores >/=i2 (22.4% vs 51.3%; ARR with infliximab, 28.9%; 95% confidence interval: 18.4% to 39.

20 the placebo group (30.6% vs 60.0%; ARR with infliximab, 29.4%; 95% confidence interval: 18.6% to 40.

21 2014: 36 received adalimumab and 44 received infliximab; 39 received concomitant thiopurines during p

22 6; 22%), diclofenac (6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (4%).

23 clinical remission while being treated with infliximab, 42 (58.3%) required additional immunomodulat

24 ocated in 1:1 ratio to two treatment groups: infliximab 5 mg/kg at 1 mg/mL intravenously over 2 h or

25 randomly to receive intravenous infusions of infliximab 5 mg/kg at weeks 0, 2, 6, and 14 plus daily o

26 spitals in the USA to assess the addition of infliximab (5 mg per kg) to standard therapy.

27 e randomly allocated (1:1) to receive either infliximab (5 mg/kg intravenous infusion given over 2 h

28 Both groups received infliximab (5 mg/kg of body weight) at weeks 1, 3, 7, an

29 Three infusions of the TNF antagonist infliximab (5 mg/kg) (n = 30) or placebo (n = 30) at bas

30 Infusion of infliximab (5 mg/kg) or normal saline after resuscitatio

31 were randomly assigned (1:1) to groups given infliximab (5 mg/kg) or placebo every 8 weeks for 200 we

32 spontaneous circulation, 14 animals received infliximab, 5 mg/kg, infused over 30 mins.

33 The most commonly used biologic agent was infliximab (67.3%).

34 95% CI, 205-1914), 1 of 148 patients taking infliximab (675 of 100,000; 95% CI, 184-718), and 1 of 1

35 vs 20.0%; absolute risk reduction [ARR] with infliximab, 7.1%; 95% confidence interval: -1.3% to 15.5

36 line; 155/188 [82.4%]) and prior exposure to infliximab (82/188 [43.6%]).

37 dence interval [CI], 0.94-1.49) and 1.97 for infliximab (95% CI, 1.50-2.43).

38 limumab (95% CI, 2.9-5.0) and 7.3 months for infliximab (95% CI, 6.2-8.3; P < .0001).

39 Infliximab, a tumor necrosis factor antagonist, is effec

40 ministration for the treatment of CD, namely infliximab, adalimumab and certolizumab pegol (CZP).

41 total serum level of 3 anti-TNFalpha drugs (infliximab, adalimumab, and certolizumab) was measured,

42 Infliximab, adalimumab, and etanercept were incubated wi

43 MMP3 and MMP12 cleaved infliximab, adalimumab, and etanercept, releasing a 32-k

44 th IBD reduced the integrity and function of infliximab, adalimumab, and etanercept.

45 nhibition differ and currently include mAbs (infliximab, adalimumab, and golimumab), either chimeric

46 ptopurine (6-MP)] and newer biologic agents (infliximab, adalimumab, and natalizumab).

47 methotrexate, azathioprine/6-mercaptopurine, infliximab, adalimumab, certolizumab, vedolizumab, or co

48 ss treatment cohorts, including ustekinumab, infliximab, adalimumab, etanercept, and nonbiologics (wi

49 Infliximab administration was associated with clinical i

50 transgenic (hTNF-Tg) mice were treated with infliximab after development of arthritis.

51 significantly higher fecal concentrations of infliximab after the first day of treatment than patient

52 we compared methotrexate and infliximab with infliximab alone in 126 patients with CD who had initiat

53 e, although safe, was no more effective than infliximab alone in patients with CD receiving treatment

54 ine,compared with 22.1% (17 of 77) receiving infliximab alone(P =.017) and 23.7% (18 of 76) receiving

55 ethotrexate results in greater efficacy than infliximab alone.

56 tial superiority of combination therapy over infliximab alone.

57 e treated 5XFAD/Tg197 mice systemically with infliximab, an anti-huTNF-alpha antibody that does not p

58 nged significantly since the introduction of infliximab, an immunomodulator considered particularly e

59 did not differ significantly (11 [11.2%] for infliximab and 11 [11.3%] for placebo; p=0.81).

60 Infliximab and adalimumab can be considered as first-lin

61 Infliximab and adalimumab can be considered as potential

62 Infliximab and adalimumab can be considered as second-li

63 Infliximab and adalimumab can be considered in these pat

64 After MMP degradation, infliximab and adalimumab functioned as F(ab')2 fragment

65 The immunogenicity of infliximab and adalimumab is a major concern because pat

66 nti-TNF-alpha biologic agents (in particular infliximab and adalimumab) are effective in the treatmen

67 i-tumor necrosis factor (TNF) agents such as infliximab and adalimumab, and etanercept is not effecti

68 se who were treated for at least 1 year with infliximab and an antimetabolite agent experienced a rel

69 e treated for at least 1 year with scheduled infliximab and an antimetabolite and had been in cortico

70 Infliximab, the combination of infliximab and azathioprine (infliximab + azathioprine),

71 The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combinat

72 Infliximab and canakinumab were used to neutralize TNF a

73 Infliximab and ciclosporin are of similar efficacy in tr

74 Relationships between serum concentration of infliximab and efficacy outcomes were assessed using tre

75 in metabolic profiles during treatment with infliximab and etanercept in RA and PsA may reflect dist

76 The reporting rates for infliximab and etanercept were compared with the backgro

77 ce plasmon resonance analysis indicated that infliximab and FpFinfliximab maintained binding affinity

78 Both Infliximab and FpFinfliximab suppressed ocular inflammat

79 two cohorts from phase 3 clinical trials of infliximab and golimumab, high pretreatment expression o

80 The combination of infliximab and methotrexate, although safe, was no more

81 ing remission, except for the combination of infliximab and methotrexate.

82 elationships between serum concentrations of infliximab and outcomes of adults with moderate-to-sever

83 lthough the relationship between exposure to infliximab and response varied among patients, approxima

84 G1m17,1 mAbs, such as infliximab and rituximab, were shown to bind more effici

85 Infliximab and steroids are currently the two agents tha

86 Adalimumab, etanercept, infliximab and tocilizumab all showed statistically sign

87 abatacept), tumor necrosis factor inhibitor (infliximab), and interleukin-6 inhibitor (tocilizumab) w

88 ly recommended, and methotrexate, acitretin, infliximab, and apremilast are recommended.

89 Adalimumab, infliximab, and infliximab + azathioprine were superior

90 ll biological agents (adalimumab, golimumab, infliximab, and vedolizumab) resulted in more clinical r

91 occurred in 2 patients (1 patient receiving infliximab,and 1 patient receiving azathioprine).

92 Infliximab (anti-TNF) treatment of UC decreased circulat

93 the progression of the disease, for example infliximab (anti-TNF-[Formula: see text]) and tocilizuma

94 Alternatives to infliximab are ADA and golimumab.

95 Serum concentrations of infliximab are associated with efficacy in patients with

96 (7 and 98 day) response to cyclosporine and infliximab are comparable.

97 Methotrexate and infliximab are effective therapies for Crohn's disease (

98 During the period of adoption of infliximab as a novel treatment for Crohn's disease, ove

99 rates are observed with anti-TNF Abs (e.g., infliximab) as compared with TNF receptor fusion protein

100 our necrosis factor alpha antibodies such as infliximab, as well as older cytotoxic medications such

101 ing D1(A12) or anti-human TNF-alpha antibody infliximab at 10 mg/kg q7d, quantifying IGROV1-Luc tumou

102 All patients received 4 to 5 mg/kg infliximab at 4- to 8-week intervals.

103 pproximate serum concentrations of 41 mug/mL infliximab at week 8 of induction therapy and 3.7 mug/mL

104 Median serum concentrations of infliximab at weeks 8, 30, and/or 54 were significantly

105 : adalimumab (OR, 2.5; 95% CrI, 1.4-4.6) and infliximab + azathioprine (OR, 2.6; 95% CrI, 1.3-6.0).

106 .1), infliximab (OR, 1.6; 95% CrI, 1.0-2.5), infliximab + azathioprine (OR, 3.0; 95% CrI, 1.7-5.5) fo

107 risons of anti-tumor necrosis factor agents, infliximab + azathioprine (OR, 3.1; 95% CrI, 1.4-7.7) an

108 d on a network meta-analysis, adalimumab and infliximab + azathioprine are the most effective therapi

109 Adalimumab, infliximab, and infliximab + azathioprine were superior to azathioprine/

110 Adalimumab and infliximab + azathioprine were superior to certolizumab:

111 combination of infliximab and azathioprine (infliximab + azathioprine), adalimumab, and vedolizumab

112 pic examination at week 26 of treatment with infliximab, azathioprine, or both.

113 ed in 62.8% (49 of 78) of patients receiving infliximab/azathioprine, compared with 54.6% (42 of 77)

114 ed by 39.7% (31 of 78) of patients receiving infliximab/azathioprine,compared with 22.1% (17 of 77) r

115 Infliximab-based therapy could, thus, still be of import

116 th ASC should receive either cyclosporine or infliximab before surgery as long as there is specialist

117 horoidopathy patients (44 eyes) who received infliximab between July 2005 and June 2012 were identifi

118 oxicity was associated with azathioprine and infliximab, but the actual number of cases attributed to

119 We discovered that Dexamethasone and Infliximab can both modulate the adaptive remodeling of

120 her prevalence of psoriatic arthritis in the infliximab cohort).

121 the ustekinumab, etanercept, adalimumab, and infliximab cohorts, respectively, and 1.05 and 1.28 per

122 n infusion occurred in patients treated with infliximab compared with 13 (13.4%) patients given place

123 sk of serious infections with adalimumab and infliximab compared with nonmethotrexate and nonbiologic

124 Serum trough infliximab concentrations may correlate with outcome.

125 Infliximab concentrations were measured in serum and sup

126 After initiating infliximab, control of inflammation was achieved in 81.8

127 hTNF-Tg mice treated with infliximab demonstrated significant clinical and histolo

128 ts in small, randomized clinical trials with infliximab demonstrating no benefit and etanercept leadi

129 that additional perioperative treatment with infliximab diminishes initiation of the inflammatory cas

130 However, infliximab does reduce endoscopic recurrence.

131 domly assigned (1:1) to groups that received infliximab dosing based on their clinical features (n =

132 been occasionally associated with the use of infliximab, etanercept, and in a lesser extent adalimuma

133 tus, smoking, significant infection history, infliximab exposure, and adalimumab exposure were each a

134 o analyze two high-purity mAbs (NIST mAb and Infliximab) expressed in a murine cell line.

135 After stopping the infliximab for infusion-related reactions he presented w

136 ng is superior to clinically based dosing of infliximab for maintaining remission in patients with CD

137 Combination therapy with azathioprine and infliximab for ulcerative colitis has now been shown to

138 ave different half-lives, their influence on infliximab (G1m17,1 allotype) pharmacokinetics was inves

139 nificantly more in infliximab group than non-infliximab group (all P < 0.05).

140 tion group versus 172.0 (164.3-179.6) in the infliximab group (mean difference 6.1 points, 95% CI -4.

141 resection group versus 1.4 days (4.7) in the infliximab group (p<0.0001), days not able to take part

142 135 patients were allocated to the infliximab group and 135 to the ciclosporin group.

143 ents were enrolled and randomised: 98 to the infliximab group and 98 to placebo.

144 A smaller proportion of patients in the infliximab group had a clinical recurrence before or at

145 Participants in the infliximab group had a greater mean reduction in C-react

146 cantly smaller proportion of patients in the infliximab group had endoscopic recurrence based only on

147 cantly smaller proportion of patients in the infliximab group had endoscopic recurrence compared with

148 rs (IQR 2-6), 26 (37%) of 70 patients in the infliximab group had resection, and 19 (26%) of 73 patie

149 6 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05

150 d survival (mean AUC 564.0 [SD 241.9] in the infliximab group vs 587.0 [226.2] in the ciclosporin gro

151 f colectomy (55 [41%] of 135 patients in the infliximab group vs 65 [48%] of 135 patients in the cicl

152 colectomy (811 [95% CI 707-912] days in the infliximab group vs 744 [638-850] days in the ciclospori

153 25 in 17 patients); or deaths (three in the infliximab group vs none in the ciclosporin group).

154 troke work were significantly greater in the infliximab group within 30 mins of resuscitation, and th

155 verse events occurred in two patients in the infliximab group.

156 Reporting rates for malignancy showed that infliximab had a consistently higher reporting rate when

157 d with the placebo group, participants given infliximab had fewer days of fever (median 1 day for inf

158 How infliximab has affected individual rates of specific typ

159 es of TNF antagonists such as etanercept and infliximab have been used successfully.

160 captopurine, nitroimidazole antibiotics, and infliximab have broadened the spectrum of medication opt

161 Small studies of etanercept and infliximab have showed these TNF-alpha blockers to be we

162 higher for those treated with adalimumab vs infliximab (hazard ratio [HR] 13.4, P = .01, 95% CI: 2.2

163 n etanercept (HR 1.63; 95% CI: 1.45-1.84) or infliximab (HR 1.56; 95% CI: 1.16-2.09) were more likely

164 Infliximab (IFX) is a chimeric mAb that can lead to the

165 Infliximab (IFX) is a therapeutic monoclonal antibody us

166 LH in pediatric patients with IBD exposed to infliximab (IFX) with patients not exposed to biologics

167 oncentration of a therapeutic drug antibody, infliximab (IFX), is recommended for enhancing its effic

168 ligated (BDL) rats with PH were treated with Infliximab (IFX, a monoclonal antibody against TNF) and

169 Perioperative infliximab in addition to tacrolimus may decrease the in

170 gnificant difference between ciclosporin and infliximab in clinical effectiveness.

171 We evaluated the efficacy of infliximab in preventing postoperative recurrence of CD

172 ings call into question the effectiveness of infliximab in preventing the need for surgery for Crohn'

173 High fecal concentrations of infliximab in the first days after therapy begins are as

174 on in kidney transplantation and response to Infliximab in ulcerative colitis.

175 on in kidney transplantation and response to Infliximab in ulcerative colitis.

176 tigated the concentrations of adalimumab and infliximab in umbilical cord blood of newborns and rates

177 ravenous cyclophosphamide, methotrexate, and infliximab) in these patients may be associated with low

178 osis factor (TNF) medications, in particular infliximab, in patients who relapse upon tapering steroi

179 Infliximab induces a high rate of complete clinical remi

180 adverse events were directly attributable to infliximab infusion.

181 agents (paclitaxel, oxaliplatin, rituximab, infliximab, irinotecan, and other drugs).

182 he G1m3,-1 mAb cetuximab, which explains why infliximab is a better competitor for endogenous IgG1 in

183 Infliximab is an antibody that neutralizes TNF-alpha and

184 n with these organisms in patients receiving infliximab is at least 5 times as frequent as would be e

185 Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interve

186 The data suggest that infliximab is effective for controlling inflammation in

187 itis, recent data show that prolonged use of infliximab is effective, well tolerated and that early m

188 Infliximab is lost into stools of patients with UC.

189 ults of network meta-analysis suggested that infliximab is more effective to induce clinical response

190 Infliximab is not superior to placebo in preventing clin

191 may identify patients for whom intravitreal infliximab is preferable to systemic treatment.

192 b cross-reacts with murine TNF-alpha whereas infliximab is species specific.

193 Infliximab is used successfully as a potent anti-inflamm

194 atient with Crohn's disease who discontinued infliximab (Janssen, Canada, Inc.) and review of the pub

195 n), based off the original product Remicade (infliximab, Janssen).

196 In a mixed leukocyte reaction infliximab led to significantly decreased proliferation

197 nd continued to improve through day 30 after infliximab (mean, 0.30; P < .0001).

198 isease, adalimumab, etanercept, ustekinumab, infliximab, methotrexate, apremilast, and golimumab are

199 ion therapy group compared with 29.8% in the infliximab monotherapy group (P = .63; hazard ratio, 1.1

200 acy and safety of 16 weeks of treatment with infliximab monotherapy, azathioprine monotherapy, or the

201 These results suggest that infliximab more often is followed by remission, off medi

202 ds or other immunosuppressant agents such as infliximab; most irAEs will resolve with appropriate man

203 Most patients received infliximab (n = 40 [87%]), with systemic steroids in 28

204 adalimumab (n=1,879), etanercept (n=1,098), infliximab (n=96), and ustekinumab (n=450) were availabl

205 t screening, 115 of 263 patients had a TC of infliximab of 3-7 mug/mL (43.7%).

206 e scheduled to begin therapy with biologics (infliximab or adalimumab) were included, with enrollment

207 knockout mice were injected once with either infliximab or adalimumab, alone or preincubated with TNF

208 duals with IBD, exposure to corticosteroids, infliximab or adalimumab, metronidazole, hospitalization

209 PsA patients before and during therapy with infliximab or etanercept.

210 oking status, previous thiopurines, previous infliximab or methotrexate, previous surgery, duration o

211 oup analyses (previous thiopurines, previous infliximab or methotrexate, previous surgery, duration o

212 ine: adalimumab (OR, 2.9; 95% CrI, 1.6-5.1), infliximab (OR, 1.6; 95% CrI, 1.0-2.5), infliximab + aza

213 tatic injury with anti-TNF-alpha antibodies (Infliximab) or glucocorticoids (Dexamethasone).

214 l of 1,283 RA patients receiving etanercept, infliximab, or adalimumab therapy were studied from amon

215 d new users of anti-TNF therapy (etanercept, infliximab, or adalimumab) or nonbiologic disease-modify

216 osporine, acitretin, adalimumab, etanercept, infliximab, or ustekinumab or phototherapy for psoriasis

217 ne, compared with 54.6% (42 of 77) receiving infliximab (P = .295) and 36.8% (28 of 76) receiving aza

218 ents with moderate to severe UC treated with infliximab plus azathioprine were more likely to achieve

219 The TNFalpha inhibition groups received infliximab post-reperfusion; etanercept pre-reperfusion

220 ms developed after 3 years of treatment with infliximab, prednisone, and methotrexate.

221 ers at time of birth (adalimumab, r = -0.80; infliximab, r = -0.80; P < .0001 for both).

222 ical cord (adalimumab: r = -0.64, P = .0003; infliximab: r = -0.77, P < .0001) and in mothers at time

223 Additional perioperative treatment with infliximab reduces early unspecific inflammatory respons

224 Furthermore, treating mice with infliximab (Remicade), a clinically used TNF-specific an

225 h chronic, recalcitrant uveitis treated with infliximab (Remicade; Janssen Biotech, Inc., Titusville,

226 ing immune complexes with TNF-alpha, an anti-infliximab response was elicited.

227 .5 mg/kg daily plus placebo infusions on the infliximab schedule; or combination therapy with the 2 d

228 ignificant relationships between quartile of infliximab serum concentration and efficacy at these tim

229 ated relapsing uveitis and that intravitreal infliximab should be considered when systemic administra

230 e value of measuring serum concentrations of infliximab should be performed before these data can be

231 Infliximab significantly improved 7-day survival and red

232 Infliximab significantly reduced both acute IRI and, as

233 therapy with prednisone (strategy 3) or with infliximab (strategy 4), all followed by targeted treatm

234 Targeting patients' infliximab TCs to 3-7 mug/mL results in a more efficient

235 umin and a higher incidence of antibodies to infliximab than patients in other quartiles.

236 Infliximab, the combination of infliximab and azathiopri

237 er increases in LM-ht-Z were associated with infliximab therapy (P<.05), increases in albumin (P<.001

238 interquartile range [IQR]: 20.0-52.2) before infliximab therapy and 83.0 (IQR: 62.0-92.0) at follow-u

239 mporal relationship to the discontinuance of infliximab therapy and its successful treatment, without

240 verely active UC during the first 2 weeks of infliximab therapy at the University of Amsterdam hospit

241 It is important to determine whether infliximab therapy can be safely interrupted in patients

242 were reversible with corticosteroids or with infliximab therapy in 2 cases.

243 nt of HRQOL changes over time in response to infliximab therapy in children with small bowel Crohn di

244 We assessed the risk of relapse after infliximab therapy was discontinued in patients on combi

245 Six patients had adverse events; infliximab therapy was discontinued in these patients be

246 Infliximab therapy was effective for a smaller proportio

247 iagnosed small bowel Crohn disease receiving infliximab therapy were prospectively enrolled.

248 owel Crohn disease (a) change in response to infliximab therapy, (b) correlate with proxy parent or g

249 Before infliximab therapy, all patients received and failed con

250 experienced at least 1 side effect while on infliximab therapy, and 17 patients (19.3%) discontinued

251 iated with glucocorticoid, methotrexate, and infliximab therapy, and increases in albumin (P<.05) and

252 ith UC) with stable responses to maintenance infliximab therapy.

253 ld be considered a reasonable alternative to infliximab therapy.

254 nce that PML can be seen in association with infliximab therapy.

255 pared laparoscopic ileocaecal resection with infliximab to assess how they affect health-related qual

256 The addition of infliximab to primary treatment in acute Kawasaki diseas

257 We assessed whether the addition of infliximab to standard therapy (intravenous immunoglobul

258 that would predict a higher success rate of infliximab to treat various types of noninfectious uveit

259 Infliximab-treated grafts exhibited significantly less l

260 HAM-D scores (baseline to week 12) favoring infliximab-treated patients at a baseline hs-CRP concent

261 At week 2, infliximab-treated patients had greater mean reductions

262 ring treatment) of 62% (8 of 13 patients) in infliximab-treated patients vs 33% (3 of 9 patients) in

263 d responders vs nonresponders (P < .05), and infliximab-treated responders exhibited significantly gr

264 luble receptors were significantly higher in infliximab-treated responders vs nonresponders (P < .05)

265 res were found significantly decreased after infliximab treatment (all P < 0.001).

266 e initial reduction of macrophages following infliximab treatment in hTNF-Tg mice.

267 aire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for t

268 Additional infliximab treatment resulted in increased smooth muscle

269 Infliximab treatment was found to significantly improve

270 Infliximab treatment was suggested to significantly redu

271 Infliximab treatment, at least in these steatotic and ch

272 ior immunomodulatory treatments, duration of infliximab treatment, dose received, secondary side effe

273 ative colitis who were candidates to receive infliximab treatment.

274 changes distinguished between etanercept and infliximab treatment.

275 the combination of maintenance methotrexate-infliximab trial, we evaluated the potential superiority

276 cy in children were identified: 31 following infliximab use, 15 following etanercept use, and 2 follo

277 roved for psoriasis (adalimumab, etanercept, infliximab, ustekinumab) with the possibility to switch

278 ab had fewer days of fever (median 1 day for infliximab vs 2 days for placebo; p<0.0001).

279 a randomized trial to compare the ability of infliximab vs placebo to prevent CD recurrence.

280 s (16 reactions in 14 participants receiving infliximab vs ten in nine patients receiving ciclosporin

281 Mean duration of disease before starting infliximab was 58.6 months.

282 In two treatment groups (24/168 hr), infliximab was administered intravenously directly after

283 Among patients with RA, infliximab was associated with a significant increase in

284 Infliximab was cleared more slowly than adalimumab from

285 Infliximab was detected in 129 of 195 fecal samples (66%

286 Re-treatment with infliximab was effective and well tolerated in 88% of pa

287 Infliximab was found to have a shorter half-life in pati

288 In a recent study, infliximab was found to have comparable efficacy to cycl

289 The safety profile of infliximab was similar to that from previous reports.

290 Infliximab was stopped, and patients were followed up fo

291 s administration of the TNF-alpha antagonist infliximab, we encountered no overt changes in numbers o

292 Ixekizumab and infliximab were differentiated by very high efficacy but

293 .0 microg/mL [IQR, 1.6 to 5.9 microg/mL]) of infliximab were similar in patients with and without les

294 nic resection and re-anastomosis followed by infliximab which maintained full endoscopic and clinical

295 ed in 45 episodes, the most common one being infliximab, which achieved success in 80% of patients.

296 ntrolled trial, we compared methotrexate and infliximab with infliximab alone in 126 patients with CD

297 IgG2 proved to have similar modifications to Infliximab with lower relative abundances of the lysine

298 A combination of infliximab with methotrexate results in greater efficacy

299 We compared serum concentrations of infliximab with outcomes of 728 patients with moderately

300 effects of tumor necrosis factor-alpha with infliximab would prevent or minimize postresuscitation c